WO1997034644A1 - Formulations topiques pour traiter le psoriasis de l'ongle - Google Patents

Formulations topiques pour traiter le psoriasis de l'ongle Download PDF

Info

Publication number
WO1997034644A1
WO1997034644A1 PCT/EP1997/000905 EP9700905W WO9734644A1 WO 1997034644 A1 WO1997034644 A1 WO 1997034644A1 EP 9700905 W EP9700905 W EP 9700905W WO 9734644 A1 WO9734644 A1 WO 9734644A1
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
formulation according
spreading
film former
treatment
Prior art date
Application number
PCT/EP1997/000905
Other languages
German (de)
English (en)
Inventor
Walter Petri
Original Assignee
Hoechst Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Aktiengesellschaft filed Critical Hoechst Aktiengesellschaft
Priority to AU18767/97A priority Critical patent/AU1876797A/en
Priority to JP09533072A priority patent/JP2000512265A/ja
Priority to KR1019980707296A priority patent/KR20000064607A/ko
Priority to BR9708081A priority patent/BR9708081A/pt
Priority to EP97905085A priority patent/EP0888138A1/fr
Publication of WO1997034644A1 publication Critical patent/WO1997034644A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action

Definitions

  • Dithranol (local), PUVA, glucocorticoids and vitamin D analogues (local) or systemic methotrexate, retinoids, cyclosporin A treated.
  • EP 0 634 170 describes formulations for the treatment of psoriasis.
  • the invention aims to provide a formulation which does not have the disadvantages described above or has them only to a minor extent.
  • the object is achieved by using a formulation which consists of the active ingredient, at least one spreading solvent, a volatile solvent and a water-insoluble film former for the manufacture of a medicament for the treatment of nail psoriasis.
  • Spreading solvents are understood to mean compounds which are found in a test system, as in Pharm. Research / Drug Res. 31 (II), 8a, p. 1 334, 1981, give the formulations according to the invention a higher spread number than Example 12 from EP 0 226 984.
  • Volatile solvents are understood to mean compounds which have a boiling point which is below 80 ° C.
  • active ingredients come e.g. in question: leflunomide and its metabolite A 77 1726, propentofylline, pentoxifylline, cyclosporin A or glucocorticoids, e.g. Alclometasone dipropionate, amcinonide, beclomethasone dipropionate, Bendacort, betamethasone benzoate, betamethasone dipropionate, betamethasone valerate, budesonide, chlorquinaldol, clioquinol, clobetasol propionate, clobetasone butyrate, desonide, desoximetasone, dexamethasone, dichlorisone, diflorasone diacetate, diflucortolone, difluprednate, fluazacort, flucinolone acetonide, fluclorolone, fludroxycortide, Flumathasonpivalat, Fluocinolonacetonide, Fluocino
  • Penetration-promoting substances are also used in these formulations, e.g. Oleyl oleate, n-octanol, N-methylpyrrolidone, hexyl laurate.
  • Suitable film formers are, for example, substances based on cellulose nitrate or physiologically harmless polymers, as are customary, for example, in cosmetics, preferably as a mixture with cellulose nitrate.
  • Examples include polyvinyl acetate and partially saponified polyvinyl acetate, copolymers of vinyl acetate on the one hand and acrylic acid or crotonic acid or Monoalkyl maleates on the other hand, tertiary copolymers of vinyl acetate on the one hand and crotonic acid and vinyl neodecanoate, or crotonic acid and vinyl propionate on the other hand, copolymers of methyl vinyl ether and monoalkyl maleate, in particular as monobutyl maleate, copolymers of Fettklavinylester and acrylic acid or methacrylic acid, copolymers of N-vinylpyrrolidone, methacrylic acid and alkyl methacrylate, copolymers of acrylic acid and methacrylic acid
  • Suitable physiologically acceptable solvents are substances such as hydrocarbons, alcohols, ethers, ketones and esters customary in cosmetics, in particular ethanol, isopropanol or acetic acid esters of monohydric alcohols, such as ethyl and butyl acetate.
  • the formulations according to the invention can furthermore contain additives customary in cosmetics, such as phthalate or camphor-based plasticizers, dyes or colored pigments, pearlescent agents, sedimentation retardants, sulfonamide resins, silicates, fragrances, surface-active substances, for example wetting agents such as sodium dioctylsulfosuccinate (DONS) and / or PEG-400 monolaurate, Tween ® 80, lanolin derivatives, photoprotective agents such as 2-hydroxy-4-methoxybenzophenone, antibacterial and antimycotic active substances, substances with a keratolytic and / or keratoplastic action, such as ammonium sulfite, esters and salts of thioglycolic acid, urea, allantoin, enzymes, Salicylic acid, complexing agents such as edetic acid and its salts and pH-adjusting substances.
  • Colored or pigmented formulations have the advantage, for example, that they can be
  • the total concentration of the antipsoriatic active ingredients is from 0.1 to 10 percent by weight (hereinafter abbreviated as%), in particular from 0.5% to 5%.
  • the concentration of the spreading solvent is from 0.1% to 10%.
  • the concentration of the film former is from 3.0% to 35%.
  • the total concentration of volatile solvents is from 50% to 90%.
  • compositions according to the invention have the following compositions:
  • silica gel layer determined according to the method given in Pharmaceutical Research / Drug Res. 31 (II), 8a, p. 1334, 1981, which was modified for measuring liquid formulations as follows.
  • the liquid formulation to be examined was applied into the inner lumen of a glass ring which was placed in the center of the thin-layer plate. In each case 100 ⁇ l were applied at 21 ° C.
  • the total area of the spreading capacity - idealized as a circular area - was determined by determining the final value of Z.
  • Relative spreading capacity spreading capacity of the formulation divided by spreading capacity of the comparison formulation.
  • IPP isopropyl palmitate
  • An anhydrous, volatile solvent or solvent mixture is introduced and, with stirring, a spreading solvent, a film former and an antipsoriatic active ingredient are added in succession so that a solution or a suspension is formed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Birds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des formulations appropriées pour traiter le psoriasis de l'ongle et contenant un principe actif antipsoriasique, au moins un solvant d'étalement, au moins un solvant volatil et un agent filmogène.
PCT/EP1997/000905 1996-03-16 1997-02-26 Formulations topiques pour traiter le psoriasis de l'ongle WO1997034644A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU18767/97A AU1876797A (en) 1996-03-16 1997-02-26 Topical formulations for the treatment of nail psoriasis
JP09533072A JP2000512265A (ja) 1996-03-16 1997-02-26 爪の乾癬の治療のための局所投与用製剤
KR1019980707296A KR20000064607A (ko) 1996-03-16 1997-02-26 손발톱건선치료용국소제제
BR9708081A BR9708081A (pt) 1996-03-16 1997-02-26 Formulações tópicas para tratamento de psóriase de unhas
EP97905085A EP0888138A1 (fr) 1996-03-16 1997-02-26 Formulations topiques pour traiter le psoriasis de l'ongle

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19610482 1996-03-16
DE19610482.3 1996-03-16

Publications (1)

Publication Number Publication Date
WO1997034644A1 true WO1997034644A1 (fr) 1997-09-25

Family

ID=7788561

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/000905 WO1997034644A1 (fr) 1996-03-16 1997-02-26 Formulations topiques pour traiter le psoriasis de l'ongle

Country Status (8)

Country Link
EP (1) EP0888138A1 (fr)
JP (1) JP2000512265A (fr)
KR (1) KR20000064607A (fr)
AU (1) AU1876797A (fr)
BR (1) BR9708081A (fr)
CA (1) CA2248977A1 (fr)
WO (1) WO1997034644A1 (fr)
ZA (1) ZA972180B (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0913154A1 (fr) * 1997-08-21 1999-05-06 Hoechst Marion Roussel Deutschland GmbH Vernis à ongles antipsoriatique
WO2005018585A1 (fr) * 2003-08-25 2005-03-03 Bioequal Ag Formulations pharmaceutiques et cosmetiques pour le traitement des ongles
US11547735B2 (en) 2020-09-14 2023-01-10 Korea Institute Of Science And Technology Composition for ameliorating psoriasis symptoms containing extract of Thalictrum squarrosum steph
US11690887B2 (en) 2020-09-14 2023-07-04 Korea Institute Of Science And Technology Composition for ameliorating psoriasis symptoms containing extract of Dianthus superbus L

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008542423A (ja) * 2005-06-10 2008-11-27 ガルデルマ・ソシエテ・アノニム 皮膚を通しての薬物の制御放出方法
CA2775393C (fr) * 2012-05-02 2014-04-29 Samy Saad Formulations pharmaceutiques topiques non aqueuses
KR102327827B1 (ko) 2019-11-01 2021-11-18 한국과학기술연구원 강황 추출물을 유효성분으로 포함하고 자외선 처리를 포함하는 건선 개선용 조성물
KR102527907B1 (ko) 2020-09-14 2023-05-03 한국과학기술연구원 무산상자 추출물을 유효성분으로 포함하는 건선 개선용 조성물
KR20230041257A (ko) 2021-09-17 2023-03-24 한국과학기술연구원 시미시푸고라이드 에이를 유효성분으로 포함하는 건선 개선용 조성물
KR20230041255A (ko) 2021-09-17 2023-03-24 한국과학기술연구원 눈개승마 추출물을 유효성분으로 포함하는 건선 개선용 조성물

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2397186A1 (fr) * 1977-07-15 1979-02-09 Mallinckrodt Inc Compositions de vernis a ongles et son procede de production
GB2085297A (en) * 1980-10-08 1982-04-28 Bernstein Joel Edward Composition for treating psoriasis of the fingernails
EP0055397A1 (fr) * 1980-12-05 1982-07-07 Bayer Ag Compositions antimycotiques à vitesse de libération élevée de la substance active et en forme de pansements liquides élastiques
WO1987002580A1 (fr) * 1985-11-04 1987-05-07 Dermatological Products Of Texas Vehicules pharmaceutiques filmogenes pour l'application de medicaments sur les ongles, compositions pharmaceutiques a base de ces vehicules, et leurs procedes d'utilisation
EP0515312A2 (fr) * 1991-05-23 1992-11-25 Sandoz Ltd. Composition pharmaceutique anti-mycotique contenant de la terbinafine
WO1995003838A1 (fr) * 1993-07-28 1995-02-09 Pfizer Inc. Traitement du psoriasis
WO1996014048A1 (fr) * 1994-11-08 1996-05-17 Seidenschnur Edel K Traitement de troubles keratiniques et psoriatiques a l'aide d'un vernis a ongles contenant un metabolite ou un derive de vitamine d et/ou un derive de vitamine a

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2397186A1 (fr) * 1977-07-15 1979-02-09 Mallinckrodt Inc Compositions de vernis a ongles et son procede de production
GB2085297A (en) * 1980-10-08 1982-04-28 Bernstein Joel Edward Composition for treating psoriasis of the fingernails
EP0055397A1 (fr) * 1980-12-05 1982-07-07 Bayer Ag Compositions antimycotiques à vitesse de libération élevée de la substance active et en forme de pansements liquides élastiques
WO1987002580A1 (fr) * 1985-11-04 1987-05-07 Dermatological Products Of Texas Vehicules pharmaceutiques filmogenes pour l'application de medicaments sur les ongles, compositions pharmaceutiques a base de ces vehicules, et leurs procedes d'utilisation
EP0515312A2 (fr) * 1991-05-23 1992-11-25 Sandoz Ltd. Composition pharmaceutique anti-mycotique contenant de la terbinafine
WO1995003838A1 (fr) * 1993-07-28 1995-02-09 Pfizer Inc. Traitement du psoriasis
WO1996014048A1 (fr) * 1994-11-08 1996-05-17 Seidenschnur Edel K Traitement de troubles keratiniques et psoriatiques a l'aide d'un vernis a ongles contenant un metabolite ou un derive de vitamine d et/ou un derive de vitamine a

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0913154A1 (fr) * 1997-08-21 1999-05-06 Hoechst Marion Roussel Deutschland GmbH Vernis à ongles antipsoriatique
US6352686B2 (en) 1997-08-21 2002-03-05 Aventis Pharma Deutschland Gmbh Antipsoriatic nail polish
WO2005018585A1 (fr) * 2003-08-25 2005-03-03 Bioequal Ag Formulations pharmaceutiques et cosmetiques pour le traitement des ongles
US11547735B2 (en) 2020-09-14 2023-01-10 Korea Institute Of Science And Technology Composition for ameliorating psoriasis symptoms containing extract of Thalictrum squarrosum steph
US11690887B2 (en) 2020-09-14 2023-07-04 Korea Institute Of Science And Technology Composition for ameliorating psoriasis symptoms containing extract of Dianthus superbus L

Also Published As

Publication number Publication date
EP0888138A1 (fr) 1999-01-07
AU1876797A (en) 1997-10-10
BR9708081A (pt) 1999-07-27
CA2248977A1 (fr) 1997-09-25
ZA972180B (en) 1997-09-16
JP2000512265A (ja) 2000-09-19
KR20000064607A (ko) 2000-11-06

Similar Documents

Publication Publication Date Title
EP0054279B1 (fr) Composition à libération retardée de nitroglycérine et sa méthode de préparation
EP0913154B1 (fr) Vernis à ongles antipsoriatique
DE69007886T2 (de) Östradiol enthaltende Mittel und Verfahren zur topischen Anwendung.
DE3882848T2 (de) Kosmetikbasiszubereitung mit arzneimitteleigenschaften.
DE69735598T2 (de) Progesterone zur behandlung oder minderung von ischemie in menopause befindlichen frauen, die östrogen bekommen
EP0298271B1 (fr) Email à ongles à activité antimycotique et procédé pour le préparer
AT400518B (de) Nagellack zur behandlung von onychomykosis enthaltend terbinafine
DE4241874A1 (de) Medizinisches Pflaster für die perkutane Verabreichung
DE2933250A1 (de) Abdeckmaterial
DE3131610A1 (de) "auflage mit einem gehalt an mikroverkapseltem nitroglyzerin, die zur perkutanten verabreichung von nitroglyzerin geeignet ist"
WO1997034644A1 (fr) Formulations topiques pour traiter le psoriasis de l'ongle
DE3690626C2 (de) Arzneimittel, enthaltend neben einer wirksamen Arzneistoffmenge ein Lacton oder cyclisches Keton
CH643456A5 (de) Pharmazeutische zubereitung.
DE60214207T2 (de) Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis
EP0100458A2 (fr) Produit pour le traitement des plaies
EP0277462B1 (fr) Procèdè de fabrication de solutions nasales contenant de la calcitonine synthètique humaine.
DE69723725T2 (de) Verfahren zur herstellung von konzentrierten lösungen von fibronectin ohne puffer
DE2924042B1 (de) Filmibildende,verspruehbare Polymerisatloesung zur Herstellung eines Wundverbandes
DE3500755C2 (fr)
CA2251702A1 (fr) Composition biologiquement active
US5800831A (en) Psoriasis treatment with polymer film
DE1266448B (de) Praeparat zum Entfernen lebloser verhornter Hautschichten
DE2852809C3 (de) Grundlage für Salben und Cremes
JPH0468286B2 (fr)
KR100220403B1 (ko) 각질 투과 증가제를 기제성분으로 함유하는 항진균성 손.발톱 와니스

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AU BB BG BR BY CA CN CZ EE GE HU IS JP KE KG KP KR KZ LK LR LT LV MD MG MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TT AT

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997905085

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2248977

Country of ref document: CA

Ref country code: CA

Ref document number: 2248977

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1019980707296

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1997905085

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1997905085

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019980707296

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1019980707296

Country of ref document: KR